119 related articles for article (PubMed ID: 12209353)
1. The efficacy of prophylactic outpatient antibiotics for the prevention of neutropenic fever associated with high-dose etoposide (VP-16) for stem cell mobilization.
Avery RK; Pohlman BL; Mossad SB; Goormastic M; Longworth DL; Kalaycio ME; Sobecks RM; Andresen SW; Kuczkowski E; Bernhard L; Ostendorf H; Wise K; Bolwell BJ
Bone Marrow Transplant; 2002 Sep; 30(5):311-4. PubMed ID: 12209353
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial.
Eleutherakis-Papaiakovou E; Kostis E; Migkou M; Christoulas D; Terpos E; Gavriatopoulou M; Roussou M; Bournakis E; Kastritis E; Efstathiou E; Dimopoulos MA; Papadimitriou CA
Am J Hematol; 2010 Nov; 85(11):863-7. PubMed ID: 20882526
[TBL] [Abstract][Full Text] [Related]
3. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies].
Delarive P; Baumgartner JD; Glauser MP; Cometta A
Schweiz Med Wochenschr; 2000 Dec; 130(48):1837-44. PubMed ID: 11132527
[TBL] [Abstract][Full Text] [Related]
5. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
6. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
[TBL] [Abstract][Full Text] [Related]
7. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity.
Gojo I; Guo C; Sarkodee-Adoo C; Meisenberg B; Fassas A; Rapoport AP; Cottler-Fox M; Heyman M; Takebe N; Tricot G
Bone Marrow Transplant; 2004 Jul; 34(1):69-76. PubMed ID: 15133484
[TBL] [Abstract][Full Text] [Related]
8. Etoposide 1.0 g/m2 or 1.5 g/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity.
Li B; Yang JL; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang S; Zhang CG
Cytotherapy; 2009; 11(3):362-71. PubMed ID: 19037766
[TBL] [Abstract][Full Text] [Related]
9. Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma.
Annunziata M; Celentano M; Pocali B; D'Amico MR; Palmieri S; Viola A; Copia C; Falco C; Del Vecchio L; Ferrara F
Ann Hematol; 2006 Jun; 85(6):394-9. PubMed ID: 16538502
[TBL] [Abstract][Full Text] [Related]
10. Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies.
Timmers GJ; Simoons-Smit AM; Leidekker ME; Janssen JJ; Vandenbroucke-Grauls CM; Huijgens PC
Clin Microbiol Infect; 2007 May; 13(5):497-503. PubMed ID: 17263835
[TBL] [Abstract][Full Text] [Related]
11. Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Assouline S; Sylvestre MP; Carriere P; Shustik C; Laneuville P
Transfusion; 2006 Feb; 46(2):174-9. PubMed ID: 16441591
[TBL] [Abstract][Full Text] [Related]
12. Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients.
Mullen CA
Pediatr Infect Dis J; 2003 Dec; 22(12):1138-42. PubMed ID: 14688588
[TBL] [Abstract][Full Text] [Related]
13. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
14. Etoposide (VP-16) plus G-CSF mobilizes different dendritic cell subsets than does G-CSF alone.
Bolwell B; Sobecks R; Pohlman B; Andresen S; Theil K; Serafino S; Rybicki L; Kalaycio M
Bone Marrow Transplant; 2003 Jan; 31(2):95-8. PubMed ID: 12621489
[TBL] [Abstract][Full Text] [Related]
15. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
[TBL] [Abstract][Full Text] [Related]
16. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support.
Gilbert C; Meisenberg B; Vredenburgh J; Ross M; Hussein A; Perfect J; Peters WP
J Clin Oncol; 1994 May; 12(5):1005-11. PubMed ID: 8164024
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide.
Hart C; Blank C; Krause SW; Andreesen R; Hennemann B
Ann Hematol; 2007 Aug; 86(8):575-81. PubMed ID: 17476507
[TBL] [Abstract][Full Text] [Related]
18. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
Park JR; Coughlin J; Hawkins D; Friedman DL; Burns JL; Pendergrass T
Med Pediatr Oncol; 2003 Feb; 40(2):93-8. PubMed ID: 12461792
[TBL] [Abstract][Full Text] [Related]
19. Outpatient high-dose melphalan in multiple myeloma patients.
Kassar M; Medoff E; Seropian S; Cooper DL
Transfusion; 2007 Jan; 47(1):115-9. PubMed ID: 17207239
[TBL] [Abstract][Full Text] [Related]
20. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
